Is Insulin Glargine a Cost-Effective Option for Treatment of Patients Naive to Insulin Treatment with Type 2, Baseline HBA1C Above 8% and Age Below 65 Years in Comparison to NPH and Premix in Poland?

Nov-08

Endocrinology Healthcare Cost Pharmacoepidemiology

AUTHORS : Prof Phil McEwan (Details for this study: Cardiff University), HEOR, Rhymney House, Unit A Copse Walk, Cardiff Gate Business Park, Cardiff, CF23 8RB – Email: enquiries@heor.co.uk – Profile: https://heor.co.uk/about-us/meet-the-team/phil-mcewan/

JOURNAL : Value in Health

REFERENCE: 11(6):A507-A508

DOI : 10.1016/S1098-3015(10)66685-5

Is Insulin Glargine a Cost-Effective Option for Treatment of Patients Naive to Insulin Treatment with Type 2, Baseline HBA1C Above 8% and Age Below 65 Years in Comparison to NPH and Premix in Poland?

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study